Display options
Cite
Emami Nejad A, Najafgholian S, Rostami A, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62doi: 10.1186/s12935-020-01719-5.
Emami Nejad, A., Najafgholian, S., Rostami, A., Sistani, A., Shojaeifar, S., Esparvarinha, M., Nedaeinia, R., Haghjooy Javanmard, S., Taherian, M., Ahmadlou, M., Salehi, R., Sadeghi, B., & Manian, M. (2021). The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer cell international, 21(1), 62. https://doi.org/10.1186/s12935-020-01719-5
Emami Nejad, Asieh, et al. "The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment." Cancer cell international vol. 21,1 (2021): 62. doi: https://doi.org/10.1186/s12935-020-01719-5
Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, Nedaeinia R, Haghjooy Javanmard S, Taherian M, Ahmadlou M, Salehi R, Sadeghi B, Manian M. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021 Jan 20;21(1):62. doi: 10.1186/s12935-020-01719-5. PMID: 33472628; PMCID: PMC7816485.
Copy Download .nbib Format: NLM
Share it on

Cancer Cell Int. 2021 Jan 20;21(1):62. doi: 10.1186/s12935-020-01719-5.

The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment.

Cancer cell international

Asieh Emami Nejad, Simin Najafgholian, Alireza Rostami, Alireza Sistani, Samaneh Shojaeifar, Mojgan Esparvarinha, Reza Nedaeinia, Shaghayegh Haghjooy Javanmard, Marjan Taherian, Mojtaba Ahmadlou, Rasoul Salehi, Bahman Sadeghi, Mostafa Manian

Affiliations

  1. Department of Biology, Payame Noor University (PNU), P.O.Box 19395-3697, Tehran, Iran.
  2. Department of Emergency Medicine, School of Medicine , Arak University of Medical Sciences, Arak, Iran.
  3. Department of Surgery, School of Medicine Amiralmomenin Hospital, Arak University of Medical Sciences, Arak, Iran.
  4. Department of Emergency Medicine, School of Medicine Valiasr Hospital, Arak University of Medical Sciences, Arak, Iran.
  5. Department of Midwifery, Faculty of Nursing and Midwifery , Arak University of Medical Sciences , Arak, Iran.
  6. Department of Immunology, School of Medicine , Tabriz University of Medical Sciences , Tabriz, Iran.
  7. Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease , Isfahan University of Medical Sciences , Isfahan, Iran.
  8. Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences , Isfahan, Iran.
  9. Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  10. Sciences Medical of University Arak, Hospital Amiralmomenin, Center Development Research Clinical, Arak, Iran.
  11. Department of Genetics and Molecular Biology, School of Medicine , Isfahan University of Medical Sciences , Isfahan, Iran.
  12. Department of Health and Community Medicine, School of Medicine, Arak University of Medical Sciences, Arak, 3848176341, Iran. [email protected].
  13. Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. [email protected].
  14. Department of Medical Laboratory Science, Faculty of Medical Science Kermanshah Branch, Islamic Azad University, Imam Khomeini Campus, Farhikhtegan Bld., Shahid J'afari St., Kermanshah, 3848176341, Iran. [email protected].

PMID: 33472628 PMCID: PMC7816485 DOI: 10.1186/s12935-020-01719-5

Abstract

Hypoxia is a common feature of solid tumors, and develops because of the rapid growth of the tumor that outstrips the oxygen supply, and impaired blood flow due to the formation of abnormal blood vessels supplying the tumor. It has been reported that tumor hypoxia can: activate angiogenesis, thereby enhancing invasiveness and risk of metastasis; increase survival of tumor, as well as suppress anti-tumor immunity and hamper the therapeutic response. Hypoxia mediates these effects by several potential mechanisms: altering gene expression, the activation of oncogenes, inactivation of suppressor genes, reducing genomic stability and clonal selection. We have reviewed the effects of hypoxia on tumor biology and the possible strategiesto manage the hypoxic tumor microenvironment (TME), highlighting the potential use of cancer stem cells in tumor treatment.

Keywords: Cancer progression; Cancer stem cells; Hypoxia; Tumor microenvironment; Tumor treatment

References

  1. Cancer Lett. 2020 Jun 1;479:23-30 - PubMed
  2. Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38 - PubMed
  3. Hepatology. 2016 Aug;64(2):473-87 - PubMed
  4. Oncotarget. 2015 Oct 27;6(33):35040-50 - PubMed
  5. Drug Resist Updat. 2011 Jun;14(3):191-201 - PubMed
  6. Pharm Res. 2014 Sep;31(9):2237-55 - PubMed
  7. Cancer Res. 1989 Dec 1;49(23):6449-65 - PubMed
  8. Cell. 2015 Sep 10;162(6):1229-41 - PubMed
  9. BMC Cancer. 2019 Feb 13;19(1):148 - PubMed
  10. J Cell Biol. 2003 Mar 3;160(5):781-91 - PubMed
  11. Nat Rev Cancer. 2011 Aug 11;11(9):671-7 - PubMed
  12. Mol Cell Biochem. 2011 Nov;357(1-2):31-8 - PubMed
  13. Trends Biochem Sci. 2012 Sep;37(9):364-72 - PubMed
  14. Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10440-5 - PubMed
  15. Exp Cell Res. 2010 Feb 15;316(4):554-67 - PubMed
  16. Clin Cancer Res. 2008 Mar 1;14(5):1340-8 - PubMed
  17. Nat Rev Cancer. 2008 Mar;8(3):180-92 - PubMed
  18. Oncotarget. 2016 Aug 23;7(34):55624-55638 - PubMed
  19. Onco Targets Ther. 2019 Oct 30;12:8947-8954 - PubMed
  20. Biol Res. 2020 Mar 14;53(1):11 - PubMed
  21. Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14391-6 - PubMed
  22. Am J Pathol. 2003 Jan;162(1):93-103 - PubMed
  23. Int J Mol Sci. 2019 Aug 27;20(17): - PubMed
  24. Genes Dev. 2006 Mar 1;20(5):557-70 - PubMed
  25. EMBO Mol Med. 2015 Feb 19;7(4):368-79 - PubMed
  26. Ann Surg. 2014 Apr;259(4):750-9 - PubMed
  27. Redox Biol. 2015 Aug;5:417 - PubMed
  28. PLoS One. 2012;7(12):e50165 - PubMed
  29. J Clin Invest. 2019 Mar 1;129(3):1030-1046 - PubMed
  30. Breast Cancer Res Treat. 2003 Sep;81(2):137-47 - PubMed
  31. J Exp Clin Cancer Res. 2018 Oct 5;37(1):245 - PubMed
  32. Nat Commun. 2015 Feb 19;6:6353 - PubMed
  33. Cancer Res. 2006 Mar 1;66(5):2725-31 - PubMed
  34. J Cell Biochem. 2020 Jan;121(1):828-839 - PubMed
  35. Proc R Soc Med. 1908;1(Surg Sect):1-13 - PubMed
  36. Nat Rev Immunol. 2005 Sep;5(9):712-21 - PubMed
  37. Nat Rev Cancer. 2016 May;16(5):275-87 - PubMed
  38. Leuk Lymphoma. 2015 Jan;56(1):26-33 - PubMed
  39. J Clin Invest. 2018 Nov 1;128(11):5137-5149 - PubMed
  40. J Exp Clin Cancer Res. 2018 Oct 19;37(1):256 - PubMed
  41. Cancer Lett. 2013 Jun 1;333(1):18-31 - PubMed
  42. Oncol Rep. 2011 Oct;26(4):1003-10 - PubMed
  43. Cell. 2013 Jul 18;154(2):311-324 - PubMed
  44. Am J Cancer Res. 2016 May 01;6(5):1078-88 - PubMed
  45. J Biol Chem. 2004 Jun 4;279(23):24218-25 - PubMed
  46. Proc Natl Acad Sci U S A. 2002 May 14;99(10):7021-6 - PubMed
  47. Tumour Biol. 2017 Mar;39(3):1010428317692261 - PubMed
  48. Int J Nanomedicine. 2018 Oct 04;13:6049-6058 - PubMed
  49. Stem Cell Res Ther. 2018 Nov 23;9(1):327 - PubMed
  50. Life Sci. 2019 Nov 15;237:116952 - PubMed
  51. Oncogene. 2012 Sep 6;31(36):4045-53 - PubMed
  52. J Biol Chem. 2016 Jun 17;291(25):12960-77 - PubMed
  53. J Clin Oncol. 2014 Oct 10;32(29):3299-306 - PubMed
  54. Nat Commun. 2017 Sep 11;8(1):517 - PubMed
  55. Immunity. 2014 Jan 16;40(1):66-77 - PubMed
  56. Methods Enzymol. 2004;381:335-54 - PubMed
  57. Leuk Lymphoma. 2017 Dec;58(12):2916-2925 - PubMed
  58. Cancer Res. 2016 Mar 15;76(6):1367-80 - PubMed
  59. Front Immunol. 2019 Dec 04;10:2762 - PubMed
  60. Mol Cancer. 2010 May 17;9:108 - PubMed
  61. J Clin Invest. 2010 Aug;120(8):2699-714 - PubMed
  62. J Cancer. 2020 Jan 1;11(1):142-152 - PubMed
  63. PLoS One. 2016 Jan 22;11(1):e0147366 - PubMed
  64. Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):253-8 - PubMed
  65. Lab Invest. 2008 Dec;88(12):1358-66 - PubMed
  66. Adv Exp Med Biol. 2019;1136:123-139 - PubMed
  67. Nature. 2016 Dec 8;540(7632):236-241 - PubMed
  68. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 - PubMed
  69. PLoS One. 2019 Apr 29;14(4):e0216055 - PubMed
  70. Oncotarget. 2017 Jun 9;8(40):67269-67286 - PubMed
  71. Med Oncol. 2001;18(4):243-59 - PubMed
  72. Am J Pathol. 2003 Sep;163(3):1001-11 - PubMed
  73. Cell Cycle. 2020 Mar;19(5):551-566 - PubMed
  74. Adv Drug Deliv Rev. 2014 Apr;69-70:205-216 - PubMed
  75. Curr Drug Targets. 2012 Dec;13(14):1858-68 - PubMed
  76. Front Oncol. 2018 Nov 20;8:527 - PubMed
  77. Am J Respir Crit Care Med. 2012 Dec 1;186(11):1180-8 - PubMed
  78. J Biol Chem. 2001 Mar 16;276(11):7919-26 - PubMed
  79. Cancer Res. 2011 Dec 15;71(24):7433-41 - PubMed
  80. Dis Model Mech. 2018 Jun 28;11(8): - PubMed
  81. Oncol Lett. 2020 Mar;19(3):2213-2222 - PubMed
  82. Mol Cancer Ther. 2010 Oct;9(10):2641-51 - PubMed
  83. Oncol Rep. 2013 Apr;29(4):1579-87 - PubMed
  84. Int J Mol Sci. 2019 Sep 01;20(17): - PubMed
  85. Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130102 - PubMed
  86. Cancer Res. 2010 Jan 15;70(2):709-18 - PubMed
  87. J Cell Mol Med. 2013 Jan;17(1):30-54 - PubMed
  88. Br J Cancer. 2019 Oct;121(8):666-678 - PubMed
  89. Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):910-20 - PubMed
  90. Nat Cell Biol. 2000 Jul;2(7):423-7 - PubMed
  91. PLoS One. 2014 Feb 13;9(2):e88913 - PubMed
  92. Cancer Cell. 2017 Nov 13;32(5):669-683.e5 - PubMed
  93. Clin Exp Pharmacol Physiol. 2017 Feb;44(2):153-161 - PubMed
  94. J Cancer. 2020 Mar 4;11(10):3052-3060 - PubMed
  95. Eur J Cancer. 1996 Dec;32A(14):2386-93 - PubMed
  96. Nature. 2014 Sep 25;513(7519):559-63 - PubMed
  97. Cell Biosci. 2011 Aug 31;1:29 - PubMed
  98. Int J Biochem Cell Biol. 2014 Apr;49:8-16 - PubMed
  99. Proc Natl Acad Sci U S A. 2008 Feb 5;105(5):1608-13 - PubMed
  100. Nat Rev Mol Cell Biol. 2008 Apr;9(4):285-96 - PubMed
  101. Cancer Cell Int. 2020 Aug 10;20:384 - PubMed
  102. Nature. 1989 May 4;339(6219):58-61 - PubMed
  103. Oncologist. 2004;9 Suppl 5:4-9 - PubMed
  104. Mol Cell Biol. 2017 Feb 15;37(5): - PubMed
  105. BMC Cancer. 2019 Jun 24;19(1):618 - PubMed
  106. Biotechnol Adv. 2018 Jul - Aug;36(4):1094-1110 - PubMed
  107. Oncotarget. 2015 Aug 14;6(23):19413-27 - PubMed
  108. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6334-9 - PubMed
  109. Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74 - PubMed
  110. Stem Cell Res Ther. 2014 Oct 14;5(5):116 - PubMed
  111. J Transl Med. 2012 Nov 19;10:226 - PubMed
  112. Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 - PubMed
  113. J Clin Oncol. 2005 Dec 10;23(35):8932-41 - PubMed
  114. Expert Opin Ther Pat. 2016 Aug;26(8):947-56 - PubMed
  115. Semin Oncol. 2001 Apr;28(2 Suppl 8):29-35 - PubMed
  116. J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 - PubMed
  117. Int J Exp Pathol. 2011 Apr;92(2):73-8 - PubMed
  118. Sci STKE. 2007 Oct 09;2007(407):cm8 - PubMed
  119. J Biol Chem. 2011 Sep 16;286(37):32843-53 - PubMed
  120. J Cell Physiol. 2010 Jul;224(1):242-9 - PubMed
  121. Semin Radiat Oncol. 2009 Apr;19(2):106-11 - PubMed
  122. Cancer Res. 2011 Jan 1;71(1):225-33 - PubMed
  123. Cancer Res. 2002 Jun 15;62(12):3387-94 - PubMed
  124. PLoS One. 2013 Aug 22;8(8):e71978 - PubMed
  125. Cancer Cell. 2007 Jan;11(1):69-82 - PubMed
  126. Oncogene. 2011 Nov 17;30(46):4609-21 - PubMed
  127. Cell Rep. 2017 Sep 12;20(11):2547-2555 - PubMed
  128. Int J Mol Sci. 2019 Sep 23;20(19): - PubMed
  129. Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 - PubMed
  130. Breast Cancer Res. 2001;3(5):328-31 - PubMed
  131. Front Pharmacol. 2020 Feb 06;11:25 - PubMed
  132. Theranostics. 2020 Jan 19;10(5):2405-2421 - PubMed
  133. Mol Cell Biol. 2007 Mar;27(5):1859-67 - PubMed
  134. Neuro Oncol. 2017 Jul 1;19(7):887-896 - PubMed
  135. Cancer Cell. 2004 Nov;6(5):507-16 - PubMed
  136. Cancer Res. 2000 Feb 1;60(3):636-43 - PubMed
  137. Oncol Res. 2016;23(5):257-66 - PubMed
  138. Drug Des Devel Ther. 2015 Apr 28;9:2399-407 - PubMed
  139. PLoS One. 2011 Apr 22;6(4):e19139 - PubMed
  140. Sci Rep. 2015 Jul 23;5:12291 - PubMed
  141. Cancer Res. 2010 Oct 1;70(19):7465-75 - PubMed
  142. Front Oncol. 2019 Oct 24;9:1104 - PubMed
  143. Blood. 2009 Jul 9;114(2):469-77 - PubMed
  144. Sci China Life Sci. 2010 Jan;53(1):101-106 - PubMed
  145. J Biol Chem. 2006 Apr 7;281(14):9030-7 - PubMed
  146. Stem Cell Reports. 2019 Jun 11;12(6):1190-1200 - PubMed
  147. Cell. 2009 Aug 7;138(3):592-603 - PubMed
  148. Nat Rev Cancer. 2006 Nov;6(11):846-56 - PubMed
  149. J Clin Neurosci. 2012 Nov;19(11):1568-72 - PubMed
  150. Cancer Res. 2009 Aug 15;69(16):6704-12 - PubMed
  151. Cell Rep. 2017 Aug 15;20(7):1641-1653 - PubMed
  152. J Leukoc Biol. 2018 Nov;104(5):911-918 - PubMed
  153. Nature. 2011 Jul 13;475(7355):226-30 - PubMed
  154. Am J Clin Oncol. 1984 Dec;7(6):617-24 - PubMed
  155. Wei Sheng Wu Xue Bao. 2014 Oct 4;54(10):1228-34 - PubMed
  156. Cancer Res. 2011 Jul 1;71(13):4628-39 - PubMed
  157. Int J Med Sci. 2018 Jan 1;15(1):86-94 - PubMed
  158. Cancer Cell. 2013 Dec 9;24(6):695-709 - PubMed
  159. Clin Pharmacol Ther. 2011 Apr;89(4):491-502 - PubMed
  160. Mol Cell Biol. 2003 Jan;23(1):359-69 - PubMed
  161. J Exp Med. 2014 May 5;211(5):781-90 - PubMed
  162. J Clin Invest. 2010 Jan;120(1):127-41 - PubMed
  163. Cancer Res. 2009 Jan 1;69(1):358-68 - PubMed
  164. Cancer Res. 2016 Mar 15;76(6):1381-90 - PubMed
  165. J Biol Chem. 2010 Feb 26;285(9):6658-69 - PubMed
  166. EMBO J. 2004 May 5;23(9):1949-56 - PubMed
  167. Cancer Res. 2016 Jun 1;76(11):3136-44 - PubMed
  168. Eur Urol. 2016 Oct;70(4):623-632 - PubMed
  169. J Carcinog Mutagen. 2013;Suppl 13:005 - PubMed
  170. Hepatology. 2016 Sep;64(3):797-813 - PubMed
  171. EMBO Rep. 2008 Jun;9(6):582-9 - PubMed
  172. J Cell Biochem. 2017 Oct;118(10):3237-3248 - PubMed
  173. Microcirculation. 1997 Mar;4(1):25-33 - PubMed
  174. Springerplus. 2013 Jul 04;2(1):301 - PubMed
  175. J Exp Med. 2010 Oct 25;207(11):2439-53 - PubMed
  176. Methods Mol Biol. 2010;651:1-29 - PubMed
  177. Front Cell Neurosci. 2015 Mar 17;9:86 - PubMed
  178. Cancer Metastasis Rev. 1994 Jun;13(2):139-68 - PubMed
  179. Cell Metab. 2005 Jun;1(6):401-8 - PubMed
  180. J Oncol. 2011;2011: - PubMed
  181. Front Immunol. 2019 Oct 16;10:2401 - PubMed
  182. Brain Res. 2008 Oct 21;1236:185-93 - PubMed
  183. BMC Cancer. 2019 Jun 4;19(1):536 - PubMed
  184. Mol Cancer. 2019 Nov 11;18(1):157 - PubMed
  185. Cancer Res. 2012 Oct 1;72(19):5130-40 - PubMed
  186. Biochem Biophys Res Commun. 2008 Feb 8;366(2):335-9 - PubMed
  187. Front Immunol. 2019 Oct 15;10:2453 - PubMed
  188. Oncotarget. 2016 Nov 15;7(46):75763-75773 - PubMed
  189. Dig Liver Dis. 2007 Jan;39(1):60-9 - PubMed
  190. PLoS One. 2010 Aug 27;5(8):e12445 - PubMed
  191. J Control Release. 2009 Dec 16;140(3):277-83 - PubMed
  192. Cell Rep. 2015 Feb 3;10(4):562-73 - PubMed
  193. Oxid Med Cell Longev. 2019 Nov 14;2019:8201079 - PubMed
  194. Respir Res. 2015 Nov 09;16:138 - PubMed
  195. Nat Rev Cancer. 2011 Feb;11(2):85-95 - PubMed
  196. J Invest Surg. 2011;24(2):67-76 - PubMed
  197. Curr Opin Otolaryngol Head Neck Surg. 2013 Apr;21(2):104-11 - PubMed
  198. Cancers (Basel). 2019 Oct 23;11(11): - PubMed
  199. Cancer Res. 2009 Feb 1;69(3):1221-9 - PubMed
  200. Biol Cell. 2016 Mar;108(3):51-64 - PubMed
  201. Br J Cancer. 2010 Oct 12;103(8):1215-20 - PubMed
  202. Nature. 2005 Dec 15;438(7070):932-6 - PubMed
  203. Stem Cells. 2008 Jul;26(7):1818-30 - PubMed
  204. J Cell Sci. 2013 Sep 15;126(Pt 18):4220-9 - PubMed
  205. Nat Rev Cancer. 2008 Feb;8(2):121-32 - PubMed
  206. Cancers (Basel). 2019 May 30;11(6): - PubMed
  207. Proc Natl Acad Sci U S A. 2013 May 21;110(21):8644-9 - PubMed
  208. Recent Pat Anticancer Drug Discov. 2013 Jan 1;8(1):85-99 - PubMed
  209. Mol Oncol. 2018 Nov;12(11):1949-1964 - PubMed
  210. Am J Pathol. 2003 Oct;163(4):1437-47 - PubMed
  211. Blood. 2004 Nov 1;104(9):2940-2 - PubMed
  212. Curr Drug Targets. 2014;15(14):1293-301 - PubMed
  213. Clin Cancer Res. 2017 May 15;23(10):2382-2390 - PubMed
  214. Cancer Treat Rev. 2014 Jul;40(6):750-9 - PubMed
  215. Int J Mol Sci. 2017 Jul 25;18(8): - PubMed
  216. Cell Cycle. 2007 Aug 1;6(15):1919-26 - PubMed
  217. Cancer Cell. 2015 Dec 14;28(6):785-799 - PubMed
  218. Nat Immunol. 2013 Nov;14(11):1173-82 - PubMed
  219. Cancer Immunol Immunother. 2018 Sep;67(9):1331-1348 - PubMed
  220. Breast Cancer Res. 2001;3(5):289-93 - PubMed
  221. Cancer Cell. 2003 Apr;3(4):347-61 - PubMed
  222. Biochim Biophys Acta. 2012 Dec;1826(2):272-96 - PubMed
  223. Cancer Res. 2012 Jan 1;72(1):335-45 - PubMed
  224. Asian Pac J Cancer Prev. 2019 Apr 29;20(4):1223-1228 - PubMed
  225. Breast Cancer Res. 2019 Dec 18;21(1):145 - PubMed
  226. Cell Physiol Biochem. 2018;49(4):1659-1676 - PubMed
  227. Cell Death Differ. 2012 Feb;19(2):284-94 - PubMed
  228. Hypoxia (Auckl). 2015 Dec 11;3:83-92 - PubMed
  229. Sci Rep. 2016 Feb 24;6:21860 - PubMed
  230. Nat Rev Cancer. 2016 Aug 23;16(9):582-98 - PubMed
  231. J Cancer Res Clin Oncol. 2020 Jan;146(1):19-31 - PubMed
  232. J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54 - PubMed
  233. Cancer Res. 2006 Dec 15;66(24):11736-44 - PubMed
  234. Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):633-44 - PubMed
  235. Cancer Treat Rev. 2011 Feb;37(1):63-74 - PubMed
  236. Cell Cycle. 2005 Feb;4(2):256-8 - PubMed
  237. Cancer Cell. 2009 Sep 8;16(3):183-94 - PubMed
  238. J Clin Oncol. 2015 May 1;33(13):1475-81 - PubMed
  239. Nature. 2006 Apr 27;440(7088):1222-6 - PubMed
  240. J Exp Clin Cancer Res. 2018 Nov 28;37(1):291 - PubMed
  241. Cancer Gene Ther. 2016 Aug;23(8):246-53 - PubMed
  242. Cancer Res. 2006 Oct 1;66(19):9339-44 - PubMed
  243. FASEB J. 2018 Sep 6;:fj201801013R - PubMed
  244. Cancer Gene Ther. 2008 Jul;15(7):449-55 - PubMed
  245. Cancer Res. 2014 Feb 1;74(3):727-37 - PubMed
  246. Am J Transl Res. 2014 Nov 22;6(6):793-808 - PubMed
  247. Stem Cell Rev Rep. 2019 Jun;15(3):331-355 - PubMed
  248. J Bioenerg Biomembr. 2018 Jun;50(3):213-222 - PubMed
  249. PLoS One. 2006 Dec 27;1:e116 - PubMed
  250. Cancers (Basel). 2019 Jul 31;11(8): - PubMed
  251. Int J Mol Sci. 2012 Oct 29;13(11):13949-65 - PubMed
  252. Oncogene. 2010 Mar 25;29(12):1787-97 - PubMed
  253. Gynecol Oncol. 2010 Dec;119(3):543-8 - PubMed
  254. Nat Rev Cancer. 2011 Jun;11(6):393-410 - PubMed
  255. Nat Cell Biol. 2008 Feb;10(2):202-10 - PubMed
  256. Sci Transl Med. 2010 May 12;2(31):31ra34 - PubMed
  257. J Clin Invest. 2010 Mar;120(3):694-705 - PubMed
  258. Cancer Gene Ther. 2017 Feb;24(2):48-56 - PubMed
  259. Front Oncol. 2016 Apr 12;6:66 - PubMed
  260. Cancer Res. 2011 Feb 1;71(3):634-9 - PubMed
  261. Int J Mol Med. 2018 Apr;41(4):1967-1975 - PubMed
  262. Science. 2001 Apr 20;292(5516):468-72 - PubMed
  263. J Cancer. 2020 Jan 1;11(4):949-961 - PubMed
  264. Eur J Pharmacol. 2020 Aug 15;881:173282 - PubMed
  265. J Cell Mol Med. 2010 Apr;14(4):771-94 - PubMed
  266. Cancer Res. 2010 May 1;70(9):3606-17 - PubMed
  267. Cell Death Differ. 2008 Apr;15(4):667-71 - PubMed
  268. Int J Mol Med. 2015 Dec;36(6):1657-63 - PubMed
  269. Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 - PubMed
  270. Drug Resist Updat. 2007 Feb-Apr;10(1-2):13-29 - PubMed
  271. Int J Cancer. 2010 Oct 1;127(7):1535-46 - PubMed
  272. Med Res Rev. 2020 Jan;40(1):385-412 - PubMed
  273. Exp Biol Med (Maywood). 2020 Mar;245(5):465-476 - PubMed
  274. Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130108 - PubMed
  275. Oncogene. 2018 Aug;37(31):4214-4225 - PubMed
  276. PLoS One. 2010 Aug 10;5(8):e12038 - PubMed
  277. Blood. 2015 Jun 18;125(25):3917-27 - PubMed
  278. Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):E2784-93 - PubMed
  279. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  280. Redox Biol. 2019 Jul;25:101109 - PubMed
  281. Pharmacol Ther. 2016 Aug;164:152-69 - PubMed
  282. Int J Cancer. 2016 Jul 15;139(2):396-403 - PubMed
  283. Stem Cells Int. 2016;2016:1740936 - PubMed
  284. Mol Cell Biol. 2004 Apr;24(7):2875-89 - PubMed
  285. Blood. 2004 Oct 15;104(8):2224-34 - PubMed
  286. Hum Pathol. 2017 Jun;64:44-52 - PubMed
  287. Oncoimmunology. 2017 Aug 4;6(11):e1358332 - PubMed
  288. Oncogene. 2013 Oct 31;32(44):5210-9 - PubMed
  289. J Clin Invest. 2012 Apr;122(4):1427-43 - PubMed
  290. J Cell Physiol. 2020 Feb;235(2):658-665 - PubMed
  291. Molecules. 2020 Feb 11;25(4): - PubMed
  292. Cancer Res. 2008 Jan 15;68(2):605-14 - PubMed
  293. J Clin Invest. 2013 Oct;123(10):4479-88 - PubMed
  294. Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4600-9 - PubMed
  295. Eur J Immunol. 2001 Sep;31(9):2829-38 - PubMed
  296. PLoS One. 2012;7(2):e30905 - PubMed
  297. PLoS One. 2012;7(3):e33729 - PubMed
  298. Cancer Res. 2015 Sep 15;75(18):3771-87 - PubMed
  299. Mol Cancer Res. 2015 Mar;13(3):556-64 - PubMed
  300. Nature. 1998 Jul 30;394(6692):485-90 - PubMed
  301. Cancer Cell. 2004 Nov;6(5):485-95 - PubMed
  302. Oncogene. 2015 Sep 3;34(36):4758-66 - PubMed
  303. Semin Cancer Biol. 2017 Apr;43:74-89 - PubMed
  304. J Exp Med. 2012 Oct 22;209(11):2001-16 - PubMed
  305. J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6 - PubMed
  306. Cells. 2019 Dec 18;9(1): - PubMed
  307. Curr Opin Genet Dev. 2001 Jun;11(3):293-9 - PubMed
  308. Genes Cancer. 2011 Dec;2(12):1117-33 - PubMed
  309. Cancer Cell. 2006 Nov;10(5):413-23 - PubMed
  310. Cancer Res. 2007 Apr 15;67(8):3560-4 - PubMed
  311. Nat Med. 1997 Feb;3(2):177-82 - PubMed
  312. Mol Cancer Ther. 2009 May;8(5):1067-74 - PubMed
  313. Crit Rev Oncol Hematol. 2017 May;113:22-27 - PubMed
  314. FASEB J. 2002 Aug;16(10):1151-62 - PubMed
  315. Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16663-8 - PubMed
  316. Oncogene. 2009 Nov 12;28(45):3949-59 - PubMed
  317. Front Cell Dev Biol. 2016 Mar 31;4:27 - PubMed
  318. Cancer Sci. 2017 Mar;108(3):362-372 - PubMed
  319. Front Cell Dev Biol. 2019 Jan 29;7:4 - PubMed
  320. Br J Cancer. 2020 Jan;122(2):157-167 - PubMed
  321. J Clin Invest. 2001 Apr;107(7):785-90 - PubMed
  322. Microsc Res Tech. 2002 Oct 1;59(1):41-8 - PubMed
  323. Cancer Res. 1999 Nov 15;59(22):5822-9 - PubMed
  324. J Thorac Oncol. 2011 Apr;6(4):671-8 - PubMed
  325. Cancer Cell. 2007 Apr;11(4):335-47 - PubMed
  326. Signal Transduct Target Ther. 2020 Feb 7;5(1):8 - PubMed
  327. J Hematol Oncol. 2016 Jan 06;9:1 - PubMed
  328. J Cell Mol Med. 2009 Sep;13(9A):2780-6 - PubMed
  329. Cancer Cell. 2017 Sep 11;32(3):377-391.e9 - PubMed
  330. Cell Cycle. 2014;13(1):11-2 - PubMed
  331. Breast Cancer Res. 2018 Mar 6;20(1):16 - PubMed

Publication Types